■ LECTURE OVERVIEW: Hodgkin Lymphoma is a clonal B-cell malignancy characterized by the presence of pathognomonic giant tumor cells in a polymorphic background of reactive immune cells.
■ PATHOGNOMONIC HISTOLOGY & FLOW:
1. Giant Tumor Cells: The diagnostic hallmark is the Reed-Sternberg (RS) cell—a giant cell (20-40 microns) with abundant pale cytoplasm.
2. Owl Eyes: RS cells typically possess a bilobed or multilobed nucleus, with each lobe containing an extraordinarily prominent, acidophilic (pink) nucleolus surrounded by a clear halo, creating a classic 'owl-eye' appearance.
3. B-Cell Rearrangements: Though arising from mutated B-lineage cells in germinal centers, RS cells have lost their classical B-cell surface markers (such as CD20 and surface immunoglobulins).
4. Immunophenotype: Diagnostic RS cells are immunophenotypically positive for CD15 and CD30 but negative for CD45.
■ SPECIAL CLINICAL POPULATIONS & METABOLIC DEVIATIONS:
Infants display higher body water ratios and immature renal filtration capacity, whereas geriatric cohorts exhibit reduced physiologic reserves, progressive heart/renal decline, and polypharmacy interactions.
■ PEDIATRIC CONTEXT & CONTINGENCIES:
Developing cohorts present with high body-water percentages and dynamic hepatic enzyme maturation pathways.
[HY-BOARD-1154]
🌟 Dynamic Clinical Key:
Classic Hodgkin Lymphoma peaks in young adults (bimodal age distribution: 15-35 and >55 years). It typically presents with painless cervical lymphadenopathy and systemic 'B symptoms' (fever, night sweats, weight loss) driven by systemic cytokine release from tumor cells. Adjust weight-based dosing for pediatric cohorts and use the 'start low and go slow' approach for seniors. Always utilize body-surface-area or weight-based dosing calculators for pediatric populations.